Cargando…
Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects
OBJECTIVES: The aim of this study was to assess the pharmacokinetics (PK) and safety/tolerability of siponimod in healthy subjects when coadministered with (1) the moderate cytochrome P450 (CYP) 2C9 and CYP3A inhibitor fluconazole (Study A), and (2) with three different CYP2C9 genotype variants (Stu...
Autores principales: | Gardin, Anne, Ufer, Mike, Legangneux, Eric, Rossato, Gianluca, Jin, Yi, Su, Zhenzhong, Pal, Parasar, Li, Wenkui, Shakeri-Nejad, Kasra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373376/ https://www.ncbi.nlm.nih.gov/pubmed/30088221 http://dx.doi.org/10.1007/s40262-018-0700-3 |
Ejemplares similares
-
Impact of siponimod on vaccination response in a randomized, placebo-controlled study
por: Ufer, Mike, et al.
Publicado: (2017) -
In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics
por: Jin, Yi, et al.
Publicado: (2017) -
Siponimod for multiple sclerosis
Publicado: (2021) -
The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine
por: Azuma, Junichi, et al.
Publicado: (2011) -
Effect of centchroman coadministration on the pharmacokinetics of metformin in rats
por: Lal, Jawahar, et al.
Publicado: (2010)